Vectura is an emerging pharmaceutical company that is developing a range of inhaled drugs for the treatment of lung diseases and conditions where delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
Vectura’s strategy is to combine proprietary pulmonary formulation and device technologies developed by the Company with existing, off-patent drugs either for use in new indications or for a new route of administration.more
Vectura also actively licenses out its inhalation device and formulation technologies for product applications for other pharmaceutical companies and operates a well-established contract pharmaceutical development service with many years experience of successful product development.
Company HistoryVectura was formed in 1997 to focus on areas within the pharmaceutical industry where innovations in the delivery of drugs offered opportunities for the development of innovative products and services.
In 1999, the Company acquired two centres of expertise in these areas; Co-ordinated Drug Development Limited (established in 1983), that was owned by a group of six eminent UK academic pharmaceutical scientists, and the Centre for Drug Formulation Studies, that had been established at the University of Bath since 1974. These two acquisitions provided a broad base of formulation expertise (focused primarily on drugs for inhalation), an extensive intellectual property estate (including a number of novel delivery technologies), an established development services business and a talented team of scientists.
In early 2002, Vectura acquired the Aspirair® inhaler technology and the associated device engineering team from Cambridge Consultants Ltd. Over the last few years, the focus on Vectura’s activities has increasingly been on the development of its own pharmaceutical products.
Company StrategyFocus on inhalationVectura believes that inhalation represents an attractive, rapid and patient friendly route for the delivery of systemically acting drugs, as well as for drugs that are designed to act locally on the lungs themselves.
Apply proprietary technologies to existing drugsVectura has filed patent applications on a range of innovative technologies for delivering drugs to the lungs in a predictable and reproducible manner. The Company seeks to apply these technologies to drugs that have already been approved in at least one of the world’s major pharmaceutical markets, either in a new indication and/or for a new route of administration. In this way, the Company believes it can secure patent protection for its products while benefiting from a lower risk of failure than is associated with the development of new drug compounds.
Develop locally-acting and systemically-acting productsVectura is developing products for local treatment of pulmonary diseases, such as asthma, COPD and cystic fibrosis, and for the systemic treatment of conditions such as Male Erectile Dysfunction, Premature Ejaculation, and Female Sexual Dysfunction, where the use of the pulmonary route of delivery offers important advantages in terms of speed of onset of action.
License out to partners for late-stage development and commercializationVectura’s strategy is to seek to license its products to larger pharmaceutical companies, with greater financial resources and existing substantial commercial infrastructures, for the later stages of development and for commercialisation. The Company anticipates seeking such licensees once significant proof of principle has been established, typically once Phase II trials have been completed.
Generate cash flows from technology licensing and fee-for-service activitiesVectura operates a well-established contract Pharmaceutical Development Service business, Vectura PDS. It also actively looks to license its technologies to other companies. Vectura’s strategy is to invest the positive cash flows generated by these activities in the development of its own product portfolio.less
Pharmaceutical manufacturing providing material property testing and medical and...
Drug development companies and trusted suppliers offering a range of services and...
Drugs and medicines are chemical compounds that are taken by humans to promote wellness,...
Contract drug manufacturing involves the employment of an external company and outsourcing...
Vectura Group Plc
Vectura Group plc
SN14 6FH, Chippenham
- NSF International, Pharmaceutical Services Providing pharmaceutical consulting, pharmaceutical auditing and...
- Bioassay Bioassay GmbH is an independent bioanalytical contract laboratory...
- Jacek Jagiello, Ph.D. Senior Scientist Dr. Jacek Jagiello received his M.S. degree in chemistry from Jag...
- Dr Paul Kippax Product manager Dr Paul Kippax is Pharmaceutical Portfolio Manager at Malvern Ins...